Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment

Hepatology

Volumn 32, Issue 6, 2000, Pages 1386-1395

  Berg, Thomas ^a   Marques, Andreas Mas ^b   Höhne, Marina ^b   Wiedenmann, Bertram ^a   Hopf, Uwe ^a   Schreier, Eckart ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN E2; INITIATION FACTOR 2; INITIATION FACTOR 2ALPHA; NON STRUCTURAL 5A PROTEIN; PROTEIN KINASE; PROTEIN KINASE R; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; DNA FLANKING REGION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RELAPSE; REMISSION; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD;

EID: 0033653568     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.20527     Document Type: Article

References (36)

1. Randomized trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b
4. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C
5. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
6. Analysis of genotypes and amino acid residues 2209-2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
7. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
8. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
9. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
10. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
11. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus genotype 1b undergoing combination therapy
12. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response
13. How cells respond to interferons
14. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
15. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
16. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
17. Inhibition of the interferon-inducible kinase PKR by HCV E2 protein
18. Hepatitis C viral dynamics and the antiviral efficacy of interferon-α therapy
19. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
20. Dose-dependent acute clearance of hepatitis genotype 1 virus with interferon alfa
21. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
22. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A non-B hepatitis
23. PHYLIP-phylogeny interference package (version 3.2)
24. CAFASP-1: Critical assessment of fully automated structure prediction methods
25. Genetic organisation and diversity of the hepatitis C virus
26. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
27. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
28. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Qunatiplex HCV RNA assay versions 1 and 2, Roche Monitor assay and in-house limiting dilution method
29. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assay
30. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa
31. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C
32. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
33. Hepatitis C virus, the E2 envelope protein, and α-interferon resistance
34. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response
35. Interferon action in triple deficient mice reveals the existence of alternative antiviral pathways
36. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway